Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.

Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.

Abstract: The present invention provides a novel artificial triple-chain antibody comprising three polypeptide chains, wherein a first polypeptide chain comprises a first heavy-chain variable domain, a second polypeptide chain comprises a first light-chain variable domain that is paired with the first heavy-chain variable domain to form a first antigen-binding site; and a third polypeptide chain comprises a second single-domain antigen-binding site and a third single-domain antigen-binding site. The present invention also provides a polynucleotide encoding the triple-chain antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, an immunoconjugate comprising the triple-chain antibody and a pharmaceutical composition comprising the triple-chain antibody or the immunoconjugate thereof, and use of the triple-chain antibody in immunotherapy, prevention and/or diagnosis of diseases.

Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.

Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.